scholarly journals ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

2018 ◽  
Vol 20 (suppl_6) ◽  
pp. vi20-vi20
Author(s):  
Daniela A Bota ◽  
Santosh Kesari ◽  
David Piccioni ◽  
Dawit Aregawi ◽  
Patrick Roth ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Phase 1 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Who Grade ◽  
Open Label Study ◽  
Label Study

A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e14083-e14083 ◽  
Author(s):  
Daniela Annenelie Bota ◽  
Santosh Kesari ◽  
David Eric Piccioni ◽  
Dawit Gebremichael Aregawi ◽  
Patrick Roth ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Dose Escalation ◽  
Phase 1 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Who Grade ◽  
Open Label Study ◽  
Label Study

scholarly journals ACTR-45. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM)

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi10-vi10
Author(s):  
Daniela Bota ◽  
Warren Mason ◽  
Santosh Kesari ◽  
David Piccioni ◽  
Dawit Aregawi ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Phase 1 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Who Grade ◽  
Open Label Study ◽  
Label Study

scholarly journals ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi16-vi16 ◽  
Author(s):  
Daniela Bota ◽  
Annick Desjardins ◽  
Warren Mason ◽  
Santosh Kesari ◽  
Rajiv Magge ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Phase 1 ◽  
Open Label ◽  
Who Grade ◽  
Open Label Study ◽  
Label Study

scholarly journals ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi13-vi13
Author(s):  
Daniela Bota ◽  
Annick Desjardins ◽  
Warren Mason ◽  
Howard Fine ◽  
Santosh Kesari ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Phase 1 ◽  
Open Label ◽  
Who Grade ◽  
Open Label Study ◽  
Label Study

Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors

2021 ◽  
pp. molcanther.0985.2020
Author(s):  
Michael S. Gordon ◽  
John Nemunaitis ◽  
Minal Barve ◽  
Zev A. Wainberg ◽  
Erika P. Hamilton ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document